A Phase 3 interventional study of warfarin and Dabigatran dose 1 in Atrial Fibrillation and Stroke, sponsored by Boehringer Ingelheim. Completed at 984 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-17.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing warfarin in Atrial Fibrillation — 1 open to participants now, 1 under way, none of them phase 3. Warfarin · Atrial Fibrillation.
Among the 26 studies testing warfarin in Atrial Fibrillation, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2005, is one of 5 in phase 3, and was the 5th registered.
4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.
Browse Atrial Fibrillation studies →1 of the 26 studies testing warfarin in Atrial Fibrillation is open now, in 1 country. Recruiting first, the newest first:
Nicholas Carlson · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Warfarin: first FDA approval 1954 (COUMADIN). What it is approved for, and how studies give it, is on its page →
Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1985; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18,113 is above the median of 150 across 2,479 interventional studies indexed under Atrial Fibrillation.
Median enrollment 203 across the 25 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
45 studies in Atrial Fibrillation by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 45 finished, 44 (98%) have results posted.
Among the 45 studies in Atrial Fibrillation by Boehringer Ingelheim, this one is one of 2 that started in 2005, is one of 3 in phase 3, and was the 2nd registered.
Boehringer Ingelheim’s Atrial Fibrillation studies by the year they started, since 2003.
1 of the studies testing warfarin in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03862859Nicholas CarlsonThe Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing warfarin in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 45 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high risk of stroke, or systemic embolism with at least one additional risk factor (i.e. previous ischemic stroke, , or systemic embolism, left ventricular dysfunction, age >=75 years, age >=65 with either diabetes mellitus, history of coronary artery disease or hypertension)
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
twice a day
Drug: Dabigatran dose 2
once a day
Drug: warfarin
twice a day
Drug: Dabigatran dose 1
once a day
twice daily
twice a day
Yearly Event Rate for Composite Endpoint of Stroke/SEE
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Time frame: 36 months
Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Time frame: 36 months
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Time frame: 36 months
Bleeding Events (Major and Minor)
Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 Major bleeds are adjudicated, whereas minor bleeds are investigator reported.
Time frame: 36 months
Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)
Time frame: 36 months
Abnormal Liver Function Test
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST\>3xULN and total bilirubin \> 2 x ULN
Time frame: 36 months
| Milestone | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Started | 6015 | 6076 | 6022 |
| Completed | 5780 | 5824 | 5756 |
| Not completed | 235 | 252 | 266 |
| Withdrew: Lost to follow-up | 17 | 31 | 41 |
| Withdrew: Withdrawal by subject | 128 | 145 | 139 |
| Withdrew: Not treated | 32 | 17 | 24 |
| Withdrew: Other | 58 | 59 | 62 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
| yearly event rate (percentage) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Yearly Event Rate for Composite Endpoint of Stroke/SEE | 1.54 | 1.11 | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
| yearly event rate (percentage) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death | 4.85 | 4.32 | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
| yearly event rate (percentage) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death | 4.26 | 3.68 | 4.35 |
Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 Major bleeds are adjudicated, whereas minor bleeds are investigator reported.
| yearly event rate (percentage) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Major bleeds | 2.99 | 3.55 | 3.81 |
| Minor bleeds | 13.16 | 14.85 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)
| yearly event rate (percentage)] | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| intracerebral hemorrhage | 0.12 | 0.10 | 0.38 |
| intracranial hemorrhage (ICH) | 0.23 | 0.32 | 0.76 |
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST\>3xULN and total bilirubin \> 2 x ULN
| participants | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Abnormal Liver Function Test | 11 | 14 | 21 |
Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran 110 mg | — | 1,263/5,983 (21.1%) | 2,286/5,983 (38.2%) |
| Dabigatran 150 mg | — | 1,289/6,059 (21.3%) | 2,273/6,059 (37.5%) |
| Warfarin | — | 1,357/5,998 (22.6%) | 2,118/5,998 (35.3%) |
| Event | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 83/5983 | 58/6059 | 73/5998 |
| PneumoniaInfections and infestations | 74/5983 | 70/6059 | 62/5998 |
| Atrial fibrillationCardiac disorders | 64/5983 | 55/6059 | 74/5998 |
| Cardiac failureCardiac disorders | 51/5983 | 62/6059 | 65/5998 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 38/5983 | 55/6059 | 41/5998 |
| AnaemiaBlood and lymphatic system disorders | 34/5983 | 47/6059 | 33/5998 |
| Chest painGeneral disorders | 29/5983 | 45/6059 | 46/5998 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 38/5983 | 43/6059 | 45/5998 |
| FallInjury, poisoning and procedural complications | 22/5983 | 29/6059 | 43/5998 |
| Renal failure acuteRenal and urinary disorders | 42/5983 | 38/6059 | 35/5998 |
| Event | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin |
|---|---|---|---|
| DizzinessNervous system disorders | 442/5983 | 440/6059 | 536/5998 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 460/5983 | 483/6059 | 506/5998 |
| Oedema peripheralGeneral disorders | 436/5983 | 439/6059 | 440/5998 |
| FatigueGeneral disorders | 367/5983 | 361/6059 | 341/5998 |
| DyspepsiaGastrointestinal disorders | 362/5983 | 344/6059 | 83/5998 |
| DiarrhoeaGastrointestinal disorders | 347/5983 | 360/6059 | 308/5998 |
| CoughRespiratory, thoracic and mediastinal disorders | 318/5983 | 308/6059 | 343/5998 |
| NasopharyngitisInfections and infestations | 315/5983 | 309/6059 | 327/5998 |
| Back painMusculoskeletal and connective tissue disorders | 281/5983 | 272/6059 | 322/5998 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 246/5983 | 306/6059 | 318/5998 |
| Age, Continuous(years) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| Mean | 71.4 ± 8.6 | 71.5 ± 8.8 | 71.6 ± 8.6 | 71.5 ± 8.7 |
| Age, Customized(Participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| <65 | 998 | 1030 | 953 | 2981 |
| 65<= and <75 | 2668 | 2580 | 2646 | 7894 |
| >=75 | 2349 | 2466 | 2423 | 7238 |
| Sex/Gender, Customized(participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| Male | 3865 | 3840 | 3809 | 11514 |
| Female | 2149 | 2236 | 2213 | 6598 |
| Missing | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 5593 | 5660 | 5615 | 16868 |
| Hispanic or Latino | 421 | 416 | 407 | 1244 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| White | 4208 | 4268 | 4203 | 12679 |
| Black | 52 | 57 | 67 | 176 |
| Asian | 955 | 965 | 955 | 2875 |
| Other | 799 | 786 | 797 | 2382 |
| Missing | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| USA, Canada | 2166 | 2200 | 2167 | 6533 |
| Central Europe | 707 | 706 | 706 | 2119 |
| Western Europe | 1544 | 1555 | 1552 | 4651 |
| Latin America | 320 | 320 | 316 | 956 |
| Asia | 923 | 933 | 926 | 2782 |
| Other | 355 | 362 | 355 | 1072 |
| Smoking history(participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| Non-smoker | 2941 | 2993 | 3006 | 8940 |
| Smoker | 440 | 447 | 448 | 1335 |
| Ex-smoker | 2633 | 2636 | 2567 | 7836 |
| Missing | 1 | 0 | 1 | 2 |
| Regular Alcohol Consumption(participants) | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Total |
|---|---|---|---|---|
| No | 4017 | 4077 | 4040 | 12134 |
| Yes | 1996 | 1999 | 1981 | 5976 |
| Missing | 2 | 0 | 1 | 3 |
Showing the first 100 of 984 sites across 44 countries. Choose a country and city above to see the rest.
Ran from Dec 2005 to primary completion in Apr 2009, 40 months.
Results were first posted in Feb 2011, 1 year 10 months after primary completion.
Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Warfarin